$LCTX
Lineage Cell Therapeutics, Inc. Stock $lctx

$lctx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223007129 Filed on March 09, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022 Q1
Revenue	$2.400M	$1.915M	$5.237M
YoY Change	-54.17%	63.96%
Cost Of Revenue	$119.0K	$102.0K	$176.0K
YoY Change	-32.39%	-50.0%	57.14%
Gross Profit	$2.267M	$1.813M	$5.061M
YoY Change	-55.21%	88.07%	1713.98%
Gross Profit Margin	94.46%	94.67%	96.64%
Selling, General & Admin	$4.724M	$4.348M	$8.469M
YoY Change	-44.22%	-1.72%	115.22%
% of Gross Profit	208.38%	239.82%	167.34%
Research & Development	$4.185M	$4.104M	$2.988M
YoY Change	40.06%	-83.44%	-9.29%
% of Gross Profit	184.61%	226.37%	59.04%
Depreciation & Amortization	$138.0K	$173.0K	$182.0K
YoY Change	-24.18%	-9.42%	-36.36%
% of Gross Profit	6.09%	9.54%	3.6%
Operating Expenses	$8.909M	$8.452M	$11.46M
YoY Change	-22.24%	-71.06%	56.32%
Operating Profit	-$6.642M	-$6.639M	-$6.396M
YoY Change	3.85%	-76.49%	-9.28%
Interest Expense	$450.0K	-$123.0K	-$734.0K
YoY Change	-161.31%	-92.66%	-110.1%
% of Operating Profit
Other Income/Expense, Net	$435.0K	$400.0K	$37.00K
YoY Change	1075.68%	-78.99%	-102.22%
Pretax Income	-$6.207M	-$6.362M	-$7.093M
YoY Change	-12.49%	-77.29%	389.85%
Income Tax	-$1.803M	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$4.372M	-$6.354M	-$7.093M
YoY Change	-38.36%	-78.08%	389.85%
Net Earnings / Revenue	-182.17%	-331.8%	-135.44%
Basic Earnings Per Share	-$0.03	-$0.03	-$0.04
Diluted Earnings Per Share	-$0.03	-$0.04	-$41.77K
COMMON SHARES
Basic Shares Outstanding	170.1M shares	170.0M shares	169.6M shares
Diluted Shares Outstanding	170.1M shares		169.6M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$46.81M	$57.88M	$79.94M
YoY Change	-41.44%	-0.83%	28.19%
Cash & Equivalents	$15.45M	$11.36M	$78.06M
Short-Term Investments	$31.36M	$46.52M	$1.882M
Other Short-Term Assets	$2.638M	$1.828M	$1.413M
YoY Change	86.69%	-22.25%	-34.25%
Inventory
Prepaid Expenses
Receivables	$203.0K	$297.0K	$515.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$49.66M	$60.00M	$81.87M
YoY Change	-39.35%	-46.21%	26.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.584M	$5.673M	$4.548M
YoY Change	22.78%	16.44%	-11.07%
Goodwill	$10.67M	$10.67M	$10.67M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$46.66M	$46.69M
YoY Change		-0.28%
Long-Term Investments
YoY Change
Other Assets	$635.0K	$627.0K	$639.0K
YoY Change	-0.63%	-0.48%	6.32%
Total Long-Term Assets	$63.55M	$63.66M	$62.65M
YoY Change	1.44%	1.06%	-1.04%
TOTAL ASSETS
Total Short-Term Assets	$49.66M	$60.00M	$81.87M
Total Long-Term Assets	$63.55M	$63.66M	$62.65M
Total Assets	$113.2M	$123.7M	$144.5M
YoY Change	-21.67%	-29.15%	12.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.001M	$2.393M	$2.956M
YoY Change	1.52%	-32.46%	5.68%
Accrued Expenses	$404.0K	$3.833M	$4.337M
YoY Change	-90.68%	-82.65%	44.33%
Deferred Revenue	$36.60M	$38.70M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$51.00K	$36.00K	$31.00K
YoY Change	64.52%	20.0%	93.75%
Total Short-Term Liabilities	$17.23M	$18.98M	$24.59M
YoY Change	-29.96%	-59.71%	271.44%
LONG-TERM LIABILITIES
Long-Term Debt	$133.0K	$84.00K	$26.00K
YoY Change	411.54%	180.0%	0.0%
Other Long-Term Liabilities		$2.000K	$32.61M
YoY Change		-99.99%	1137.46%
Total Long-Term Liabilities	$0.00	$2.000K	$32.63M
YoY Change	-100.0%	-99.99%	1126.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.23M	$18.98M	$24.59M
Total Long-Term Liabilities	$0.00	$2.000K	$32.63M
Total Liabilities	$44.19M	$51.73M	$57.97M
YoY Change	-23.77%	-38.16%	465.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$367.7M	-$363.4M
YoY Change		7.79%
Common Stock	$441.3M	$440.3M
YoY Change		1.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$70.45M	$73.34M	$86.55M
YoY Change
Total Liabilities & Shareholders Equity	$113.2M	$123.7M	$144.5M
YoY Change	-21.67%	-29.15%	12.97%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022 Q1
OPERATING ACTIVITIES
Net Income	-$4.372M	-$6.354M	-$7.093M
YoY Change	-38.36%	-78.08%	389.85%
Depreciation, Depletion And Amortization	$138.0K	$173.0K	$182.0K
YoY Change	-24.18%	-9.42%	-36.36%
Cash From Operating Activities	-$11.24M	-$8.303M	$21.90M
YoY Change	-151.32%	41.38%	-395.04%
INVESTING ACTIVITIES
Capital Expenditures	$188.0K	-$16.00K	-$46.00K
YoY Change	-508.7%	-89.04%	318.18%
Acquisitions
YoY Change
Other Investing Activities	$15.61M	-$5.118M	$0.00
YoY Change			-100.0%
Cash From Investing Activities	$15.43M	-$5.102M	-$46.00K
YoY Change	-33634.78%	3394.52%	-100.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.000K	122.0K	513.0K
YoY Change	-99.81%	-87.21%	-97.55%
NET CHANGE
Cash From Operating Activities	-$11.24M	-8.303M	21.90M
Cash From Investing Activities	$15.43M	-5.102M	-46.00K
Cash From Financing Activities	$1.000K	122.0K	513.0K
Net Change In Cash	$4.085M	-13.28M	22.37M
YoY Change	-81.74%	162.25%	-5.26%
FREE CASH FLOW
Cash From Operating Activities	-$11.24M	-$8.303M	$21.90M
Capital Expenditures	$188.0K	-$16.00K	-$46.00K
Free Cash Flow	-$11.43M	-$8.287M	$21.95M
YoY Change	-152.07%	44.7%	-396.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000876343
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	LCTX	Liability Classified Warrants Current Portion LiabilityClassifiedWarrantsCurrentPortion		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	LCTX	Revenue Grants RevenueGrants		usd
CY2022	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2022	LCTX	Marketable Securities Gain MarketableSecuritiesGain		usd
CY2021	LCTX	Accretion Of Income On Marketable Debt Securities AccretionOfIncomeOnMarketableDebtSecurities		usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities		usd
CY2022	LCTX	Proceeds From Sale Of Investment ProceedsFromSaleOfInvestment		usd
CY2022	LCTX	Proceeds From Sale Of Investment Two ProceedsFromSaleOfInvestmentTwo		usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	LCTX	Receivable From Sale Of Common Shares In At Market Offering ReceivableFromSaleOfCommonSharesInAtMarketOffering		usd
CY2022	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer		usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent		usd
CY2021	LCTX	Effective Income Tax Rate Reconciliation Withholding Tax EffectiveIncomeTaxRateReconciliationWithholdingTax		pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential		pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022Q4	LCTX	Deferred Tax Asset Operating Lease Liability DeferredTaxAssetOperatingLeaseLiability		usd
CY2021Q4	LCTX	Deferred Tax Asset Capitalized Research Expense DeferredTaxAssetCapitalizedResearchExpense		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-12830
CY2022	dei	Entity Registrant Name EntityRegistrantName	Lineage Cell Therapeutics, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CA
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3127919
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	2173 Salk Avenue
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Carlsbad
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92008
CY2022	dei	City Area Code CityAreaCode	442
CY2022	dei	Local Phone Number LocalPhoneNumber	287-8990
CY2022	dei	Security12b Title Security12bTitle	Common shares
CY2022	dei	Trading Symbol TradingSymbol	LCTX
CY2022	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	200600000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	170145713	shares
CY2022	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2022	dei	Auditor Location AuditorLocation	San Francisco, California
CY2022	dei	Auditor Firm AuditorFirmId	100
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11355000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55742000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	46520000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2616000	usd
CY2022Q4	LCTX	Accounts And Grants Receivable Net Current AccountsAndGrantsReceivableNetCurrent	297000	usd
CY2021Q4	LCTX	Accounts And Grants Receivable Net Current AccountsAndGrantsReceivableNetCurrent	50840000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1828000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2351000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	60000000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	111549000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5673000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4872000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	627000	usd
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	630000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	10672000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	10672000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	46692000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	46822000	usd
CY2022Q4	us-gaap	Assets Assets	123664000	usd
CY2021Q4	us-gaap	Assets Assets	174545000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8608000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	27969000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	916000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	801000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	36000	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	30000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	9421000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	18119000	usd
CY2021Q4	LCTX	Liability Classified Warrants Current Portion LiabilityClassifiedWarrantsCurrentPortion	197000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18981000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	47116000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2076000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2076000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	27725000	usd
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	32454000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2860000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1941000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	84000	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	30000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	30000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	51728000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	83647000	usd
CY2022Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2021Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2021Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	170093000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	170093000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	169477000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	169477000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	440280000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	434529000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3571000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5211000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-363370000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-337097000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	73339000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	92221000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-1403000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-1323000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71936000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	90898000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	123664000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	174545000	usd
CY2022	LCTX	Collaboration Revenues CollaborationRevenues	13367000	usd
CY2021	LCTX	Collaboration Revenues CollaborationRevenues	1120000	usd
CY2022	LCTX	Royalties Royalties	1336000	usd
CY2021	LCTX	Royalties Royalties	2776000	usd
CY2021	LCTX	Revenue Grants RevenueGrants	445000	usd
CY2022	us-gaap	Revenues Revenues	14703000	usd
CY2021	us-gaap	Revenues Revenues	4341000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	728000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	1426000	usd
CY2022	us-gaap	Gross Profit GrossProfit	13975000	usd
CY2021	us-gaap	Gross Profit GrossProfit	2915000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13987000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33914000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22508000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18212000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	36495000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	52126000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-22520000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-49211000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	829000	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2000	usd
CY2021	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	6024000	usd
CY2022	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-2194000	usd
CY2021	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-2299000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	523000	usd
CY2022	LCTX	Gain On Revaluation Of Warrant Liability GainOnRevaluationOfWarrantLiability	225000	usd
CY2021	LCTX	Gain On Revaluation Of Warrant Liability GainOnRevaluationOfWarrantLiability	205000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2152000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1486000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3292000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5941000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25812000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-43270000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	541000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-26353000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-43270000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-80000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-251000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-26273000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-43019000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	169792000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	164502000	shares
CY2022	us-gaap	Profit Loss ProfitLoss	-26353000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-43270000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1790000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1544000	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-150000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-24713000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-44814000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-80000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-251000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24633000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44563000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	95127000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	29817000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-54000	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	202000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3519000	usd
CY2021	LCTX	Shares Issued Upon Exercise Of Stock Options SharesIssuedUponExerciseOfStockOptions	7429000	usd
CY2021	LCTX	Financing Related Fees FinancingRelatedFees	-330000	usd
CY2021	LCTX	Shares Issued Upon Exercise Of Stock Options1 SharesIssuedUponExerciseOfStockOptions1	2000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1544000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-43270000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	90898000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	90898000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-17000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4287000	usd
CY2022	LCTX	Shares Issued Upon Exercise Of Stock Options SharesIssuedUponExerciseOfStockOptions	490000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	991000	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-150000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1790000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-26353000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71936000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71936000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-26273000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-43019000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-80000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-251000	usd
CY2021	LCTX	Marketable Securities Gain MarketableSecuritiesGain	6024000	usd
CY2022	LCTX	Marketable Securities Unrealized Gain Loss1 MarketableSecuritiesUnrealizedGainLoss1	-2194000	usd
CY2021	LCTX	Marketable Securities Unrealized Gain Loss1 MarketableSecuritiesUnrealizedGainLoss1	-2299000	usd
CY2022	LCTX	Accretion Of Income On Marketable Debt Securities AccretionOfIncomeOnMarketableDebtSecurities	501000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	582000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	663000	usd
CY2022	LCTX	Change In Rightofuse Assets And Liabilities ChangeInRightofuseAssetsAndLiabilities	-35000	usd
CY2021	LCTX	Change In Rightofuse Assets And Liabilities ChangeInRightofuseAssetsAndLiabilities	14000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	145000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	210000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4287000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	3519000	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	202000	usd
CY2022	LCTX	Gain On Revaluation Of Warrant Liability Related To Operating Activites GainOnRevaluationOfWarrantLiabilityRelatedToOperatingActivites	225000	usd
CY2021	LCTX	Gain On Revaluation Of Warrant Liability Related To Operating Activites GainOnRevaluationOfWarrantLiabilityRelatedToOperatingActivites	205000	usd
CY2022	LCTX	Foreign Currency Remeasurement And Other Gain Loss ForeignCurrencyRemeasurementAndOtherGainLoss	-2272000	usd
CY2021	LCTX	Foreign Currency Remeasurement And Other Gain Loss ForeignCurrencyRemeasurementAndOtherGainLoss	1566000	usd
CY2022	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	11000	usd
CY2021	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	-24000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	523000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-50314000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	857000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-446000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	72000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-18702000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	21645000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-13354000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	380000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1059000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23561000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	53412000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	7666000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	413000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	340000	usd
CY2021	LCTX	Proceeds From Sale Of Investment ProceedsFromSaleOfInvestment	10064000	usd
CY2021	LCTX	Proceeds From Sale Of Investment Two ProceedsFromSaleOfInvestmentTwo	21000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-46159000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9745000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	648000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7240000	usd
CY2022	LCTX	Common Shares Received And Retired For Employee Taxes Paid CommonSharesReceivedAndRetiredForEmployeeTaxesPaid	17000	usd
CY2021	LCTX	Common Shares Received And Retired For Employee Taxes Paid CommonSharesReceivedAndRetiredForEmployeeTaxesPaid	54000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	148000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	30865000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	991000	usd
CY2022	LCTX	Repayment Of Financing Lease Liabilities RepaymentOfFinancingLeaseLiabilities	32000	usd
CY2021	LCTX	Repayment Of Financing Lease Liabilities RepaymentOfFinancingLeaseLiabilities	20000	usd
CY2022	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	106000	usd
CY2021	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	1101000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1632000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	36930000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-873000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-20000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-44341000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23094000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56277000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	33183000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11936000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56277000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	13000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	13000	usd
CY2021	LCTX	Receivable From Sale Of Common Shares In At Market Offering ReceivableFromSaleOfCommonSharesInAtMarketOffering	147000	usd
CY2022	LCTX	Receivable From Exercise Of Stock Options ReceivableFromExerciseOfStockOptions	32000	usd
CY2021	LCTX	Receivable From Exercise Of Stock Options ReceivableFromExerciseOfStockOptions	189000	usd
CY2018	us-gaap	Proceeds From Collaborators ProceedsFromCollaborators	14300000	usd
CY2022Q4	LCTX	Cash And Cash Equivalents And Marketable Securities CashAndCashEquivalentsAndMarketableSecurities	57900000	usd
CY2022Q4	LCTX	Available For Sale Of Securities Value Reserved For Future Issuance AvailableForSaleOfSecuritiesValueReservedForFutureIssuance	63800000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11355000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55742000	usd
CY2022Q4	us-gaap	Other Restricted Assets Current OtherRestrictedAssetsCurrent	581000	usd
CY2021Q4	us-gaap	Other Restricted Assets Current OtherRestrictedAssetsCurrent	535000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11936000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56277000	usd
CY2022Q4	LCTX	Accounts Receivables Amounted AccountsReceivablesAmounted	300000	usd
CY2021Q4	LCTX	Accounts Receivables Amounted AccountsReceivablesAmounted	50800000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	100000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	100000	usd
CY2022	LCTX	Goodwill And In Process Research And Development GoodwillAndInProcessResearchAndDevelopment	<p id="xdx_84C_ecustom--GoodwillAndInProcessResearchAndDevelopment_zTNYdLiwMjW7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_z831Zot00WO9">Goodwill and IPR&D</span></i> – Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is tested for impairment in accordance with ASU 2017-04, <i>Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</i>. In-process research and development (“IPR&D”) assets are indefinite-lived intangible assets until the completion or abandonment of the associated research and development (“R&D”) efforts. Once the R&D efforts are completed or abandoned, the IPR&D will either be amortized over the asset’s estimated life as a finite-lived intangible asset or be impaired, respectively, in accordance with ASC 350, <i>Intangibles – Goodwill and Other</i>. In accordance with ASC 350, goodwill and acquired IPR&D are determined to have indefinite lives and, therefore, are not amortized. Instead, they are tested for impairment at least annually and between annual tests if we become aware of an event or a change in circumstances that would indicate the asset may be impaired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	4100000	usd
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	52300000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zB6mzEXBQRub" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_z7edp1C36wxl">Concentrations of credit risk and significant sources of supply</span></i> – Financial instruments that potentially subject Lineage to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable debt securities. Lineage limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, Lineage has not experienced any losses on such accounts. Lineage mitigates its credit exposure on marketable debt securities by investing in short term U.S. Treasuries securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lineage relies on single-source, third-party suppliers for a few key components of our product candidates. If these single-source, third-party suppliers are unable to continue providing a key component, the initiation or progress of any clinical studies of its product candidates may be impeded.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Revenues Revenues	14703000	usd
CY2021	us-gaap	Revenues Revenues	4341000	usd
CY2022	us-gaap	Revenues Revenues	14700000	usd
CY2021	us-gaap	Revenues Revenues	4300000	usd
CY2022	LCTX	Upfront Payment UpfrontPayment	50000000.0	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	297000	usd
CY2022	LCTX	Comprehensive Gain Foreign Currency Translation Adjustments Net Of Tax ComprehensiveGainForeignCurrencyTranslationAdjustmentsNetOfTax	1800000	usd
CY2021	LCTX	Comprehensive Loss Foreign Currency Translation Adjustments Net Of Tax ComprehensiveLossForeignCurrencyTranslationAdjustmentsNetOfTax	1500000	usd
CY2021	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	445000	usd
CY2021	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	445000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	13367000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1120000	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	50640000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	37146000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	50500000	usd
CY2021Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	200000	usd
CY2021Q1	us-gaap	Deferred Revenue DeferredRevenue	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	38700000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	37100000	usd
CY2022Q4	LCTX	Unfulfilled Commitments UnfulfilledCommitments	1600000	usd
CY2022Q4	LCTX	Deferred Revenues DeferredRevenues	37100000	usd
CY2022Q4	LCTX	Deferred Revenue Current1 DeferredRevenueCurrent1	9400000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	53220000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	46247000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	152000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	46097000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	46247000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	46097000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	46247000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	46097000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5850000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5302000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5673000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4872000	usd
CY2022Q4	LCTX	Financing Leases Related To Property And Equipment FinancingLeasesRelatedToPropertyAndEquipment	121000	usd
CY2021Q4	LCTX	Financing Leases Related To Property And Equipment FinancingLeasesRelatedToPropertyAndEquipment	118000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	582000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	663000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	10672000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	10672000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	66143000	usd
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	66143000	usd
CY2022Q4	LCTX	Accumulated Amortization Of Intangible Assets AccumulatedAmortizationOfIntangibleAssets	19451000	usd
CY2021Q4	LCTX	Accumulated Amortization Of Intangible Assets AccumulatedAmortizationOfIntangibleAssets	19321000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	46692000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	46822000	usd
CY2022	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	46500000	usd
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	152000	usd
CY2022	LCTX	Amortization Of Intangible Assets Write Off Value AmortizationOfIntangibleAssetsWriteOffValue	100000	usd
CY2021	LCTX	Amortization Of Intangible Assets Write Off Value AmortizationOfIntangibleAssetsWriteOffValue	200000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	130000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	22000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	152000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2393000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3543000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2382000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2162000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3833000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22086000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	178000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8608000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	27969000	usd
CY2022	us-gaap	Redemption Premium RedemptionPremium	21000000.0	usd
CY2022	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	3500000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2022Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	170093114	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	170093114	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	169477347	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	169477347	shares
CY2022	LCTX	Effective Income Tax Rate Reconciliation Withholding Tax EffectiveIncomeTaxRateReconciliationWithholdingTax	-0.02	pure
CY2022	LCTX	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.02	pure
CY2021	LCTX	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.01	pure
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4287000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	3519000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	500000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25812000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-43270000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.03	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.01	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.28	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.16	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.07	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.08	pure
CY2022	LCTX	Effective Income Tax Rate Reconciliation State And Local Income Taxes Gilti Inclusion EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesGiltiInclusion	-0.01	pure
CY2021	LCTX	Effective Income Tax Rate Reconciliation State And Local Income Taxes Gilti Inclusion EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesGiltiInclusion	-0.12	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.01	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.02	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	58816000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	68766000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	10463000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	9466000	usd
CY2022Q4	LCTX	Deferred Tax Asset Parents And Licenses DeferredTaxAssetParentsAndLicenses	1500000	usd
CY2021Q4	LCTX	Deferred Tax Asset Parents And Licenses DeferredTaxAssetParentsAndLicenses	1403000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2308000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1717000	usd
CY2021Q4	LCTX	Deferred Tax Asset Operating Lease Liability DeferredTaxAssetOperatingLeaseLiability	134000	usd
CY2022Q4	LCTX	Deferred Tax Asset Capitalized Research Expense DeferredTaxAssetCapitalizedResearchExpense	3066000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2555000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1608000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	78708000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	83094000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	78209000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	70967000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	499000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	12127000	usd
CY2022Q4	LCTX	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	4000	usd
CY2021Q4	LCTX	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	115000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2464000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	13299000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	107000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	789000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2575000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14203000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2076000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2076000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	150600000	usd
CY2021Q4	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate	50000000.0	usd
CY2022	LCTX	Measurement Period Adjustment Income Tax Expense Benefit MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit	1700000	usd
CY2021	LCTX	Measurement Period Adjustment Income Tax Expense Benefit MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit	24800000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1047000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	935000	usd
CY2022	LCTX	Operating Cash Flows From Financing Leases OperatingCashFlowsFromFinancingLeases	3000	usd
CY2021	LCTX	Operating Cash Flows From Financing Leases OperatingCashFlowsFromFinancingLeases	13000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	32000	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	20000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2286000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	213000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	90000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	39000	usd
CY2021Q4	LCTX	Upfront Payment Cost UpfrontPaymentCost	50000000.0	usd
CY2021Q4	us-gaap	Development Costs DevelopmentCosts	620000000.0	usd
CY2022Q1	us-gaap	Loss Contingency Receivable Proceeds LossContingencyReceivableProceeds	50000000.0	usd
CY2022Q4	LCTX	Grants Awarded Percentage GrantsAwardedPercentage	0.50	pure
CY2021Q4	LCTX	Royalty Payment Percentage RoyaltyPaymentPercentage	0.243	pure
CY2022Q4	LCTX	Aggregate Cap Amount AggregateCapAmount	91200000	usd
CY2021Q4	LCTX	Sublicensing Fee Percentage SublicensingFeePercentage	0.215	pure
CY2021Q4	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate	50000000.0	usd
CY2017Q2	LCTX	Royalty Payment Percentage RoyaltyPaymentPercentage	0.50	pure
CY2022Q1	us-gaap	Revenues Revenues	5237000	usd
CY2022Q2	us-gaap	Revenues Revenues	4553000	usd
CY2022Q3	us-gaap	Revenues Revenues	2998000	usd
CY2022Q4	us-gaap	Revenues Revenues	1915000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	11457000	usd
CY2022	LCTX	Defined Contribution Plan Maximum Contributions Percent DefinedContributionPlanMaximumContributionsPercent	0.050	pure
CY2021	LCTX	Defined Contribution Plan Maximum Contributions Percent DefinedContributionPlanMaximumContributionsPercent	0.050	pure
CY2022	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	200000	usd
CY2021	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	200000	usd
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	subsidiary
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14703000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4341000	usd
CY2022Q4	us-gaap	Noncurrent Assets NoncurrentAssets	5673000	usd
CY2021Q4	us-gaap	Noncurrent Assets NoncurrentAssets	4872000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14703000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4341000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	8572000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	8014000	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	8452000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6396000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4234000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5251000	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-6639000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7087000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-6763000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-6069000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-6354000	usd
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2021Q1	us-gaap	Revenues Revenues	391000	usd
CY2021Q2	us-gaap	Revenues Revenues	512000	usd
CY2021Q3	us-gaap	Revenues Revenues	2270000	usd
CY2021Q4	us-gaap	Revenues Revenues	1168000	usd
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	7329000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	7467000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	8128000	usd
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	29202000	usd
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7050000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7080000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6843000	usd
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-28238000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-1416000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-4788000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-7823000	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-28992000	usd
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17

Files In Submission

Name	View Source	Status
lctx-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-007129-index-headers.html	Edgar Link	pending
0001493152-23-007129-index.html	Edgar Link	pending
0001493152-23-007129.txt	Edgar Link	pending
0001493152-23-007129-xbrl.zip	Edgar Link	pending
ex10-07.htm	Edgar Link	pending
ex10-21.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_003.jpg	Edgar Link	pending
form10-k_004.jpg	Edgar Link	pending
form10-k_005.jpg	Edgar Link	pending
form10-k_006.jpg	Edgar Link	pending
form10-k_007.jpg	Edgar Link	pending
lctx-20221231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
lctx-20221231_cal.xml	Edgar Link	unprocessable
lctx-20221231_def.xml	Edgar Link	unprocessable
lctx-20221231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LCTX
Lineage Cell Therapeutics, Inc. Stock $lctx

2023 Q1 Form 10-K Financial Statement

#000149315223007129 Filed on March 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LCTX Lineage Cell Therapeutics, Inc. Stock $lctx

2023 Q1 Form 10-K Financial Statement

#000149315223007129 Filed on March 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LCTX
Lineage Cell Therapeutics, Inc. Stock $lctx